The central hypothesis driving Project 1 is that the clinical efficacy of magnetic nanoparticle (mNP)-based cancer therapies can be substantially enhanced by precise targeting ofthe particles to cancer cells. Previous efforts using antibody and antibody fragments to target nanoparticles has yielded mixed results, and the fragmented nature ofthe related literature does not permit drawing informative conclusions that might guide future studies. To remedy this stark deficit of knowledge regarding targeting of mNP cancer therapies. Project 1 will, in a controlled fashion, conjugate genetically engineered single-chain antibody fragments (scFvs) to the surface of custom-designed mNPs. These mNP immunoconjugates will be subjected to rigorous physical, biochemical, and functional characterization. Upon establishing stringent control of mNP immunoconjugate manufacturing and characterization processes, controlled studies will systematically evaluate three key parameters believed to be critical for clinical efficacy of targeted mNP cancer therapies: (1) mNP specificity and affinity for target cells;(2) the subcellular localization of mNP upon reaching their targets;and (3) the relationship between mNP size and cellular/tumor accumulation of mNP, as assessed in two different cancer models?breast cancer and ovarian cancer.
Aim 1 will test the hypothesis that simultaneously targeting two different cancer-associated cell surface receptors with a single mNP will increase avid interactions between targeted particles and cancer cells, thereby improving specificity and biodistribution.
Aim 2 will test the hypothesis that mNPs are targeted to cancer-antigen-expressing cells more effectively by internalizing antibodies than by non-internalizing antibodies.
Aim 3 will test the hypothesis that smaller (10-20 nm) mNP immunoconjugates accumulate in antigen-expressing tumors to a higher level than larger (50-100 nm) mNP immunoconjugates. The objectives of these aims will be achieved by integrating knowledge of antibody-engineering technologies, experience with bioconjugation chemistry, and expertise with in vitro analysis of cellular mNP accumulation. The project will draw on the Nanoparticle Development, Production, and Characterization Core for mNP fabrication, on Projects 3 &4 for coordinated testing of mNP immunoconjugates in vivo, and on the Toxicology, Pathology, and Biodistribution Core and the Biostatistics, Data Analysis, and Computation Core for analysis of those in vivo results.

Public Health Relevance

The key to any cancer therapy is preferential toxicity toward malignant cells verses healthy tissue. In the context of magnetic nanoparticle therapies, it is clear that passive targeting of tumors is insufficient for practical clinical efficacy. Looking to the future, the nanotechnologist will employ genetically engineered biomolecules to precisely guide magnetic nanoparticle therapies to cancerous cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA151662-05
Application #
8710046
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
5
Fiscal Year
2014
Total Cost
$240,852
Indirect Cost
$77,347
Name
Dartmouth College
Department
Type
DUNS #
041027822
City
Hanover
State
NH
Country
United States
Zip Code
03755
Rutkowski, Melanie R; Stephen, Tom L; Svoronos, Nikolaos et al. (2015) Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell 27:27-40
Stephen, Tom L; Rutkowski, Melanie R; Allegrezza, Michael J et al. (2014) Transforming growth factor ?-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression. Immunity 41:427-39
Reeves, Daniel B; Weaver, John B (2014) Approaches for modeling magnetic nanoparticle dynamics. Crit Rev Biomed Eng 42:85-93
Toraya-Brown, Seiko; Sheen, Mee Rie; Zhang, Peisheng et al. (2014) Local hyperthermia treatment of tumors induces CD8(+) T cell-mediated resistance against distal and secondary tumors. Nanomedicine 10:1273-85
Tichauer, Kenneth M; Deharvengt, Sophie J; Samkoe, Kimberley S et al. (2014) Tumor endothelial marker imaging in melanomas using dual-tracer fluorescence molecular imaging. Mol Imaging Biol 16:372-82
Tichauer, Kenneth M; Samkoe, Kimberley S; Gunn, Jason R et al. (2014) Microscopic lymph node tumor burden quantified by macroscopic dual-tracer molecular imaging. Nat Med 20:1348-53
Samkoe, Kimberley S; Tichauer, Kenneth M; Gunn, Jason R et al. (2014) Quantitative in vivo immunohistochemistry of epidermal growth factor receptor using a receptor concentration imaging approach. Cancer Res 74:7465-74
Perreard, I M; Reeves, D B; Zhang, X et al. (2014) Temperature of the magnetic nanoparticle microenvironment: estimation from relaxation times. Phys Med Biol 59:1109-19
Ficko, Bradley W; Nadar, Priyanka M; Hoopes, P Jack et al. (2014) Development of a magnetic nanoparticle susceptibility magnitude imaging array. Phys Med Biol 59:1047-71
Russell, Stewart; Samkoe, Kimberley S; Gunn, Jason R et al. (2014) Spatial frequency analysis of anisotropic drug transport in tumor samples. J Biomed Opt 19:15005

Showing the most recent 10 out of 30 publications